Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1 Unknown
24 enrolled
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Phase 1 Unknown
112 enrolled
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Phase 1 Unknown
198 enrolled
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Phase 1 Unknown
48 enrolled
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Phase 1 Unknown
40 enrolled
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
Phase 1 Unknown
24 enrolled
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
Phase 1 Unknown
36 enrolled
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Phase 1 Unknown
60 enrolled
SILTUXILAM
Phase 1 Unknown
12 enrolled
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Unknown
18 enrolled
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase 1 Unknown
38 enrolled
Natural Killer(NK) Cell Therapy in r/r AML
Phase 1 Unknown
18 enrolled
PANDA-T0
Phase 1 Unknown
5 enrolled
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 1 Unknown
57 enrolled
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
Phase 1 Unknown
10 enrolled
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 Unknown
73 enrolled
ILDA
Phase 1 Unknown
12 enrolled
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Phase 1 Unknown
10 enrolled
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
Phase 1 Unknown
30 enrolled
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1 Unknown
58 enrolled
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
Phase 1 Unknown
30 enrolled
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Phase 1 Unknown
40 enrolled
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
Phase 1 Unknown
42 enrolled
A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia
Phase 1 Unknown
41 enrolled
NK Cell Infusion for Patients With Acute Myeloid Leukemia
Phase 1 Unknown
10 enrolled
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
Phase 1 Unknown
75 enrolled
AMPCAL
Phase 1 Unknown
10 enrolled
NK Cells in Cord Blood Transplantation
Phase 1 Unknown
13 enrolled
Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia
Phase 1 Unknown
38 enrolled
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
Phase 1 Unknown
15 enrolled
ATAC-AML-01
Phase 1 Unknown
12 enrolled
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Phase 1 Unknown
20 enrolled
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
Phase 1 Unknown
10 enrolled
INTACT-WT1
Phase 1 Unknown
20 enrolled
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Unknown
18 enrolled
BBMPI03
Phase 1 Unknown
4 enrolled
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
Phase 1 Unknown
40 enrolled
PODAC
Phase 1 Unknown
19 enrolled
SCRAMBLE
Phase 1 Unknown
12 enrolled
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Unknown
36 enrolled
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
Phase 1 Unknown
20 enrolled
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 1 Unknown
21 enrolled
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
Phase 1 Unknown
40 enrolled
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Unknown
6 enrolled
RFUSIN2-AML1
Phase 1 Unknown
24 enrolled